The Efficacy of Augment of D-Cycloserine and Cognitive-behavioral Therapy on Adolescent with one Type of Anxiety Disorders: A Double-blind Randomized Controlled Trial

Document Type : Original Article


1 Department of Psychiatry, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran


Background: This study was designed to investigating the effect of combining D-cycloserine (DCS) and cognitive-behavioral therapy (CBT) on adolescent with at least one type of anxiety disorders. Materials and Methods: The present study was conducted as a double-blind randomized controlled trial on 36 adolescent with anxiety disorders. Patients were assessed in two groups. In addition to 4 sessions of weekly CBT in both groups; case group, received a 50-mg DCS capsules, control group, received Placebo daily for a month. Patients received DCS capsules or placebo 1 h before sessions of CBT. Age, sex, kind of anxiety disorders “screen for child anxiety related disorders (SCARED)” and “cognitive abilities test (CATS)” scores were evaluated and compared between groups. Results: The mean age of the studied patients (29 females (80.6%) and 7 males (19.4%)) was 14.1 ± 1.8 years. The most frequent anxiety disorder among the study population was generalized social disorder (GAD) (77.7%). Age, sex and the frequency of anxiety disorders were not statistically significant between the study groups (P > 0.05). The mean score of “SCARED” and “CATS” at before starting the treatment, after treatment and three month after the treatment were not statistically significant between groups (P > 0.05). Also, decrease in values of “SCARED” and “CATS” during the evaluation time periods was not statistically significant between groups (P > 0.05). Conclusions: Findings of this study showed that there has been no difference in symptoms improvement in adolescent with anxiety disorder who received treatment protocol including 4 sessions of CBT, weekly, together with 50 mgs of DCS compared to the patients of the control group.


Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.  Back to cited text no. 1
Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability, and service utilization: Overview of the Australian National Mental Health Survey. Br J Psychiatry 2001;178:145-53.  Back to cited text no. 2
Bernsrein GA, Shaw K. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Adolesc Psychiatry 1997;36:69-84.  Back to cited text no. 3
Manassis K, Mendlowitz SL, Scapilato D, Avery D, Fiksenbaum L, Freire M, et al. Group and individual congnitive: Behavioral therapy for childhood anxiety disorders: A randomaized irial. J Am acad Child Adolesc Psychiatry 2002;41:1423-30.  Back to cited text no. 4
Toren P, Wolmer L, Rosental B, Eldar S, Koren S, Lask M, et al. Case series: Brief parent child group therapy for childhood anxiety disorders using a manual based cognitive behavioral technique. J Am Acad Adolesc Psychiatry 2000;39:1309-12.  Back to cited text no. 5
Mary E, Jeffery B, Scott W, Bengt M, davis B. fluoxetine for the treatment of childhoos anxiety disorders: Open_lable, Long_term, Extension to a Controlled trial. J Am Acad Child Adolesce Psychiatry 2005;44:1263-70.  Back to cited text no. 6
John M, Malouff EB, Thorsteinsson SE, Rooke NB, Schutte. Efficacy of cognitive behavioral therapy for chronic fatigue syndrome: A meta-analysis. Clin Psychol Rev 2008;28:736-45.  Back to cited text no. 7
Zimmermann G, Favrod J, Trieu VP. The effect of congnitive behavioral treatment on the positive symptoms to schizophrenia spectrum disorders: A meta-analysis. Schizophrenia Res 2005;77:1-9.  Back to cited text no. 8
Feske V, Chambless D. Cognitive behavioral versus exposure only treatment for social phobia: A meta-analysis. Behav Ther 1995;26:695-720.  Back to cited text no. 9
Hidalgo RB, Barnett SD, Davidson JRT. Social anxiety disorder in review: Two decades of progress. Int J Neuropsychopharmacol 2001;4:279-98.  Back to cited text no. 10
Foa EB, Franklin ME, Moser J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination Biol Psychiatry 2002;10:987-97.  Back to cited text no. 11
Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: Review and analysis. Clin Psychol (New York) 2005;12:72-86.  Back to cited text no. 12
Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev 2006;12:208-17.  Back to cited text no. 13
Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-77.  Back to cited text no. 14
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-7.  Back to cited text no. 15
Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005;30:633-9.  Back to cited text no. 16
Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161:2115-7.  Back to cited text no. 17
Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI. D-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996;46:420-4.  Back to cited text no. 18
Tsai G, Falk W, Gunther J, Coyle J. Improved cognition in Alzheimer's disease with short-term Dcycloserine treatment. Am J Psychiatry 1999;156:467-9.  Back to cited text no. 19
Davis M, Walker DL, Meyers KM. Role of the amygdala in fear extinction measured with potentiated startle. Ann NY Acad Sci 2003;985:218-32.  Back to cited text no. 20
Ledgerwood L, Richardson R, Cranney J. D-cycloserine facilitates extinction of conditioned fear as assessed by freezing in rats. Behav Neurosci 2003;117:341-9.  Back to cited text no. 21
Ledgerwood L, Richardson R, Cranney J. D-cycloserine and the facilitation of conditioned fear: Consequences for reinstatement. Behav Neurosci 2004;118:505-13.  Back to cited text no. 22
Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005;83:224-31.  Back to cited text no. 23
Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learn Mem 2004;11:510-6.  Back to cited text no. 24
Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63:1118-26.  Back to cited text no. 25
Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. Biol Psychiatry 2006;60:369-75.  Back to cited text no. 26
Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136-44.  Back to cited text no. 27
Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006;63:298-304.  Back to cited text no. 28
Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63:544-9.  Back to cited text no. 29
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010;67:365-70.  Back to cited text no. 30
Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007;41:466-71.  Back to cited text no. 31
Muris P, Dressen L, Bogles S, Weckk M, Van Melick M. A questionnaire for screening broad range of DSM-defined anxiety disorder symptoms in clinically referred children and adolescents. J Am Acad Child Psychol Psychiatry 2004;45:813-20.  Back to cited text no. 32
Ganasen KA, Ipser JC, Stein DJ. Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin North Am 2010;33:687-99.  Back to cited text no. 33
Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008;63:1118-26.  Back to cited text no. 34
Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22:230-7.  Back to cited text no. 35
Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: Current treatment recommendations. CNS Drugs 2005;19:377-91.  Back to cited text no. 36
Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2010;68:1073-6.  Back to cited text no. 37
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165:335-41.  Back to cited text no. 38
Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002;(2):CD003153.  Back to cited text no. 39